Siltuximab ( DrugBank: Siltuximab )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 28 | 全身性アミロイドーシス | 1 |
| 331 | 特発性多中心性キャッスルマン病 | 7 |
28. 全身性アミロイドーシス
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03315026 (ClinicalTrials.gov) | December 14, 2017 | 13/10/2017 | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis | Multiple Myeloma;AL Amyloidosis | Drug: Siltuximab;Behavioral: The M.D. Anderson Symptom Inventory (MDASI) | Memorial Sloan Kettering Cancer Center | Janssen Scientific Affairs, LLC | Active, not recruiting | 60 Years | 75 Years | All | 30 | Phase 2 | United States |
331. 特発性多中心性キャッスルマン病
臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04838860 (ClinicalTrials.gov) | March 31, 2021 | 25/2/2021 | Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease | A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment | Idiopathic Multicentric Castleman's Disease | Drug: Siltuximab | EusaPharma (UK) Limited | NULL | Terminated | 12 Years | N/A | All | 22 | Phase 2 | United States |
| 2 | EUCTR2010-022837-27-GB (EUCTR) | 15/02/2013 | 01/08/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Germany;Norway;New Zealand;China;Korea, Republic of | ||
| 3 | EUCTR2010-022837-27-BE (EUCTR) | 17/12/2012 | 23/07/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | Phase 2 | United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Norway;Germany;New Zealand;China;Korea, Republic of | ||
| 4 | EUCTR2010-022837-27-ES (EUCTR) | 29/11/2012 | 26/09/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 15.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Germany;Norway;New Zealand;China;Korea, Republic of | ||
| 5 | EUCTR2010-022837-27-DE (EUCTR) | 21/11/2012 | 19/09/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | Phase 2 | United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Norway;Germany;New Zealand;China;Korea, Republic of | ||
| 6 | NCT01400503 (ClinicalTrials.gov) | April 1, 2011 | 21/4/2011 | A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease | Multicentric Castleman's Disease | Drug: Siltuximab | Janssen Research & Development, LLC | NULL | Completed | 18 Years | N/A | All | 60 | Phase 2 | United States;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom |
| 7 | NCT01024036 (ClinicalTrials.gov) | March 18, 2010 | 30/11/2009 | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease | Multicentric Castleman's Disease | Drug: Siltuximab;Drug: Placebo;Drug: Best Supportive Care (BSC) | Janssen Research & Development, LLC | NULL | Completed | 18 Years | N/A | All | 79 | Phase 2 | United States;Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;Jordan;Poland |